Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



Organovo Holdings, Inc.: Customers Are Knocking at Our Door

By now, many investors have heard of 3-D printing and its potential to disrupt several entrenched industries. Not only can these machines speed up the prototyping process exponentially, but some believe that there will be a 3-D printer in every household within a few decades.

But there's a much smaller segment of 3-D printing that operates under the radar of many investors: 3-D bioprinting. Although printing of organs remains the dream of many speculators, the immediate future of the technology and its largest publicly traded company -- Organovo Holdings, Inc.  (NYSEMKT: ONVO  ) -- is squarely focused on the printing of human tissues for use in drug testing.

Source: Organovo.

In its full life as a corporate entity, Organovo has brought in almost no revenue from the actual sale of products, relying instead on grants, collaborations, and funding from the public markets to finance operations. That, however, may come to an end by December. The company has shown the ability to print 3-D liver cells that mimic native cells more accurately than 2-D versions, and can remain functional for well over one month.

The idea is that pharmaceutical companies could test for liver toxicities before entering Food and Drug Administration trials. By doing so, the drug companies can save billions of dollars by either killing or adjusting the composition of their drugs before going through the costly trials.

The company's upbeat outlook
Although shares of Organovo -- a highly volatile stock -- had lost almost half of their value from 2014 highs before today, the company has issued a number of upbeat updates. First, it let investors know that the liver assays were being made available to key opinion leaders ahead of schedule and that the liver assays would be available for sale earlier than expected.

Then just today, it announced that because of customer interest and time-sensitive projects, Organovo was signing up customers for limited, pre-release availability of its liver assays. According to CEO Keith Murphy, "Organovo has received interest in advance of our planned launch from top 15 pharma company customers, small to midsize pharma companies, biotechnology companies, and private venture capital backed pharmaceutical development firms." 

Instead of issuing the liver assays to customers as the company is expected to do after a full release, these customers will contract with Organovo for toxicity tests to be conducted within Organovo's own facilities.

What this means for customers
One of the biggest arguments against owning shares of Organovo is that there are already plenty of companies -- both publicly traded and private -- that provide human tissues for the medical field. But Organovo has said all along that what it is providing -- in 3-D tissues that have a shelf life of over a month and closely mimic native tissues -- is fundamentally different from what's on the market right now.

If demand is as strong as this new information would lead some to believe, it could be great news for Organovo investors. As it is now, it's still too early to tell how successful the company's products will be on the market, but in the absence of any other news, the outlook is upbeat.

As a shareholder myself, I still plan on waiting until further results and revenue information come in before purchasing more shares.

Invest in the next wave of health-care innovation
The Economist compares this disruptive invention to the steam engine and the printing press. Business Insider says it's "the next trillion-dollar industry." And the technology behind it is poised to set off one of the most remarkable health-care revolutions in decades. The Motley Fool's exclusive research presentation dives into this technology's true potential and its ability to make life-changing medical solutions never thought possible.  To learn how you can invest in this unbelievable new technology, click here now to see our free report.

Read/Post Comments (4) | Recommend This Article (10)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On April 28, 2014, at 11:00 PM, stockanal45 wrote:

    Just a couple of years ago, ONVO used to be one of the few 3D printing human tissue companies. Now, there's dozens of them in the healthcare industry. Do you know how many patents ONVO own to protect their innovative technology from other copycat companies?

  • Report this Comment On April 29, 2014, at 9:02 AM, TMFCheesehead wrote:


    See page 9 here. The wording is a bit difficult to decipher, but it looks like the company has at least seven broad patents on their technology and its application to toxicity testing.


    Brian Stoffel

  • Report this Comment On April 29, 2014, at 11:22 AM, wazeldazel wrote:

    I bought in real low and it's worth holding on to just to see what happens..

  • Report this Comment On May 01, 2014, at 2:08 PM, oldphartt1916 wrote:

    I have a very small stake in ONVO, But, I am very intrigued with it's possibilities and plan to add more as it progresses .

    I am now starting on my 2'nd million ... The 1'st was too hard so I gave up on it !!

Add your comment.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2932600, ~/Articles/ArticleHandler.aspx, 8/27/2015 3:43:34 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Brian Stoffel

Brian Stoffel has been a Fool since 2008, and a financial journalist for the Motley Fool since 2010. He tends to follow the investment strategies of Fool-founder David Gardner, looking for the most innovative companies driving positive change for the future.

Today's Market

updated Moments ago Sponsored by:
DOW 16,460.56 175.05 1.07%
S&P 500 1,969.05 28.54 1.47%
NASD 4,759.92 62.38 1.33%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

8/27/2015 3:27 PM
ONVO $2.33 Up +0.02 +0.87%